Minimal change disease and idiopathic FSGS: manifestations of the same disease.
Rutger J Maas, Jeroen K Deegens, Bart Smeets...
https://pubmed.ncbi.nlm.nih.gov/27748392/Actively Recruiting
Led by Mario Negri Institute for Pharmacological Research · Updated on 2025-09-04
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying idiopathic nephrotic syndrome INS, which includes minimal change disease MCD and focal segmental glomerulosclerosis FSGS, and comparing it to primary membranous nephropathy MN. The goal is to evaluate the levels of circulating anti-nephrin autoantibodies, which may play a role in INS and post-transplant FSGS relapse. INS is a serious kidney condition with unclear causes and limited treatment options, especially when it recurs after transplantation. The study involves testing stored blood samples from patients with biopsy-confirmed idiopathic MCD or FSGS and those with membranous nephropathy. These samples will be analyzed using specialized ELISA tests to measure anti-nephrin autoantibody levels. The tests use recombinant nephrin protein and antibodies to detect these autoantibodies in the blood, comparing patients with INS to those with MN. Participants have previously provided consent for their samples to be stored in a certified biobank. Researchers will analyze these samples retrospectively over about one year to measure antibody levels. The study focuses on laboratory analysis without direct patient involvement, aiming to better understand the potential role of anti-nephrin autoantibodies in nephrotic syndrome and its recurrence after kidney transplant.
CONDITIONS
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
F
Federica Casiraghi, PhD
N
Norberto Perico, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mario Negri Institute for Pharmacological Research
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year to perform analysis
Participants provide serum samples which will be tested for levels of anti-nephrin autoantibodies using ELISA techniques.
1 visit for blood sample collection
Duration - Up to 1 year
Participants' serum samples are observed retrospectively to assess anti-nephrin autoantibody levels in patients with nephrotic syndrome compared to controls.
No additional visits required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rutger J Maas, Jeroen K Deegens, Bart Smeets...
https://pubmed.ncbi.nlm.nih.gov/27748392/Federica Casiraghi, Marta Todeschini, Manuel Alfredo Podestà...
https://pubmed.ncbi.nlm.nih.gov/37175393/Ellen T McCarthy, Mukut Sharma, Virginia J Savin
https://pubmed.ncbi.nlm.nih.gov/20966123/Vivette D D'Agati, Frederick J Kaskel, Ronald J Falk
https://pubmed.ncbi.nlm.nih.gov/22187987/Piero Ruggenenti, Barbara Ruggiero, Paolo Cravedi...
https://pubmed.ncbi.nlm.nih.gov/24480824/Andrew J B Watts, Keith H Keller, Gabriel Lerner...
https://pubmed.ncbi.nlm.nih.gov/34732507/Giuseppe Salfi, Federica Casiraghi, Giuseppe Remuzzi
https://pubmed.ncbi.nlm.nih.gov/37795085/Yoko Shirai, Kenichiro Miura, Kiyonobu Ishizuka...
https://pubmed.ncbi.nlm.nih.gov/38110152/Francesco Pecoraro, Luca Perico, Federica Casiraghi...
https://pubmed.ncbi.nlm.nih.gov/42048157/Lorenzo Gallon, Joseph Leventhal, Anton Skaro...
https://pubmed.ncbi.nlm.nih.gov/22533598/Mario Negri Institute for Pharmacological Research
Lead Sponsor